Can peptides help you avoid surgery?
Bottom line: Peptide-related treatments may help some people feel better and could change whether an elective operation still feels necessary. Existing studies generally measured pain, movement, weight, or scans—not the number of operations avoided. That leaves surgery prevention as an open question rather than a disproven idea.
- Best human result
- Some people with knee arthritis had less pain.
- Fewer operations shown?
- No.
- Tendon or spine repaired?
- Not yet answered in controlled human trials.
- BPC-157 and TB-500
- Promising research candidates; surgery-prevention outcomes have not been tested.
Feeling better and repairing damage are not the same
A study can measure pain, walking, weight, or a picture from a scan. Those results can matter. But proving that an operation was avoided takes more: researchers must compare similar groups, count the operations, and follow people long enough to know surgery was not simply delayed.
Think of a worn tire. Making the ride feel smoother is useful. It does not prove the tread grew back. In the same way, less joint pain does not prove that cartilage, a tendon, or a nerve was repaired.
Knee arthritis has the clearest human evidence
Semaglutide: less weight and less knee pain
The STEP 9 trial included 407 adults with obesity and moderate knee arthritis. After 68 weeks, the semaglutide group lost about 14% of its starting weight, compared with about 3% in the placebo group. On a 100-point pain scale, average pain fell about 42 points with semaglutide and 28 points with placebo.
That is a meaningful result for people who resemble the study group. It does not show that semaglutide regrew cartilage or prevented knee replacement. The study was not designed to prove either claim.
Collagen peptides: possible relief, no proven rebuilding
A 2025 trial followed 80 adults with early knee arthritis for six months. The collagen group reported better pain and movement. But the space between the knee bones on X-rays did not improve significantly.
This supports possible symptom relief. It does not show that collagen rebuilt the joint or prevented replacement surgery.
Sprifermin: a scan changed, but people did not clearly feel better
Sprifermin is an experimental protein injected into the knee. In a 549-person trial, the highest doses increased cartilage thickness on MRI by about 0.04 to 0.05 millimeters compared with placebo. Overall pain, stiffness, and movement scores were not significantly better.
This is a useful warning: a small change on a scan and a meaningful change in daily life are not the same. The trial also did not prove that sprifermin prevented knee replacement.
Tendon claims are far ahead of human research
BPC-157 and TB-500 are often used or discussed for rotator-cuff injuries, Achilles tendon problems, and other soft-tissue pain. BPC-157 now has a recruiting 120-person Phase 2 hamstring study. Published human information for TB-500 remains limited.
Patient experiences and animal studies can point researchers in the right direction. To estimate how often a peptide prevents tendon surgery, a study still needs to count operations in comparable groups over time.
Back pain and nerve pain depend on the cause
“Back pain” is not one disease. Pain may come from a disc, joint, muscle, pinched nerve, or another problem. Human trials have not yet tested whether BPC-157 or TB-500 can prevent spine surgery, and neither peptide would be expected to mechanically remove pressure from a nerve.
Ziconotide is different. It is an FDA-approved peptide medicine for selected people with severe chronic pain. It is delivered into the fluid around the spinal cord through a special pump under expert care. It can control pain, but it does not rebuild the spine or remove pressure from a nerve.
Feeling better may still change a decision
Pain relief and easier movement can be valuable. A person who can walk, sleep, and handle daily tasks may decide with a clinician that an elective operation is not needed now.
That is not the same as proving a peptide prevented surgery. The change may come from weight loss, physical therapy, improved sleep, time, or a new understanding of the diagnosis.
Our verdict: Ask one clear question: did people feel better, did a scan change, or did fewer people need an operation? Those are three different results. Peptides may eventually help with all three, but current studies have mainly answered the first two.
Do not delay urgent care
Some operations are time-sensitive. Do not cancel or delay a recommended procedure because of an article, testimonial, or seller’s promise. Ask the clinician who knows your diagnosis what could happen if you wait. When the choice is not urgent, a second medical opinion may help.
Questions to ask before deciding
- What is the exact cause of my pain?
- What is the operation meant to fix?
- Is it urgent, or is there time to try a measured non-surgical plan?
- What result would show that the plan is working?
- Did the peptide study measure pain, repair on a scan, or fewer operations?
- Would a second opinion help with this decision?
Red flags in an “avoid surgery” pitch
- A seller guarantees that a peptide will prevent an operation.
- An animal study is presented as proof of human healing.
- Less pain is treated as proof that tissue grew back.
- The seller cannot name the completed human trial.
- One stack is promoted for arthritis, tendon tears, back pain, and nerve pain.
- You are told to cancel surgery without a review of your diagnosis and records.
Primary sources
- STEP 9: semaglutide in people with obesity and knee osteoarthritis. New England Journal of Medicine, 2024. 407 participants.
- Low-molecular-weight collagen peptides in knee osteoarthritis. Frontiers in Nutrition, 2025. 80 participants.
- Sprifermin and knee-cartilage thickness. JAMA, 2019. 549 participants.
- FDA briefing document on BPC-157-related bulk drug substances. July 2026.
- Phase 2 BPC-157 hamstring-injury trial. Recruiting; no results posted as of August 11, 2026.
- FDA advisory committee meeting and materials. July 23–24, 2026.
- Associated Press report on the advisory committee vote. July 23, 2026.
- FDA briefing document on TB-500-related bulk drug substances. July 2026.
- FDA prescribing information for PRIALT (ziconotide). Revised March 2023.
Published and evidence reviewed August 11, 2026. This is general education. It cannot tell you whether to have surgery. Report a correction or new study.